Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 2;20(5):23.
doi: 10.1007/s11926-018-0736-2.

Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

Erika P Navarro-Mendoza  1 , Gabriel J Tobón  2   3
Affiliations
Review

Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies

Erika P Navarro-Mendoza et al. Curr Rheumatol Rep. .

Abstract

Purpose of review: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide.

Recent findings: With the right treatment, clinical prognosis is favorable, so concerted efforts have been made in recent years to find new alternatives for treating severe EGPA. Monoclonal antibodies such as omalizumab, rituximab, and mepolizumab are among these new options. This review summarizes the pathogenesis and clinical manifestations of EGPA and critically examines current and emerging therapies.

Keywords: Churg−Strauss syndrome; Mepolizumab; Omalizumab; Rituximab; Therapeutics.

PubMed Disclaimer

References

    1. Arthritis Rheumatol. 2015 Apr;67(4):1117-27 - PubMed
    1. Medicine (Baltimore). 1984 Mar;63(2):65-81 - PubMed
    1. N Engl J Med. 2008 Dec 25;359(26):2790-803 - PubMed
    1. N Engl J Med. 2014 Nov 6;371(19):1771-80 - PubMed
    1. J Asthma. 2016;53(2):201-6 - PubMed

MeSH terms

LinkOut - more resources